Reviewing QXO (NYSE:QXO) and Cyclacel Pharmaceuticals (NASDAQ:BGMS)

Cyclacel Pharmaceuticals (NASDAQ:BGMS) and QXO (NYSE:QXO) are both industrials companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, valuation and risk.

Valuation & Earnings

This table compares Cyclacel Pharmaceuticals and QXO”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cyclacel Pharmaceuticals	$1.86 million	2.59	-$3.00 million	($3.64)	-0.24
QXO	$9.90 billion	1.40	-$279.40 million	($0.90)	-14.79

Cyclacel Pharmaceuticals has higher earnings, but lower revenue than QXO. QXO is trading at a lower price-to-earnings ratio than Cyclacel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for Cyclacel Pharmaceuticals and QXO, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cyclacel Pharmaceuticals	1	0	0	0	1.00
QXO	1	1	13	2	2.94

QXO has a consensus target price of $28.00, suggesting a potential upside of 110.32%. Given QXO’s stronger consensus rating and higher possible upside, analysts plainly believe QXO is more favorable than Cyclacel Pharmaceuticals.

Profitability

This table compares Cyclacel Pharmaceuticals and QXO’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cyclacel Pharmaceuticals	-118.27%	-31.60%	-27.72%
QXO	-5.17%	2.41%	1.20%

Institutional and Insider Ownership

23.6% of Cyclacel Pharmaceuticals shares are owned by institutional investors. Comparatively, 58.7% of QXO shares are owned by institutional investors. 23.7% of Cyclacel Pharmaceuticals shares are owned by insiders. Comparatively, 41.0% of QXO shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

Cyclacel Pharmaceuticals has a beta of -0.4, indicating that its share price is 140% less volatile than the S&P 500. Comparatively, QXO has a beta of 2.32, indicating that its share price is 132% more volatile than the S&P 500.

Summary

QXO beats Cyclacel Pharmaceuticals on 12 of the 15 factors compared between the two stocks.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company’s development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing’s disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.

About QXO

QXO, Inc. operates as a business application, technology, and consulting company in North America. The company provides solutions for accounting and business management, financial reporting, enterprise resource planning, human capital management, warehouse management systems, customer relationship management, and business intelligence. It also offers value-added services that focuses on consulting and professional, specialized programming, training, and technical support services. In addition, the company provides information technology managed services, such as cybersecurity, application hosting, disaster recovery, business continuity, cloud, and other services; and data back-up, network maintenance, and upgrade services. It serves small and medium-sized businesses primarily in the manufacturing, distribution, and service industries. QXO, Inc. is headquartered in Greenwich, Connecticut.